Ionis Pharmaceuticals (MEX:IONS) Shares Outstanding (EOP): 166 Mil (As of Mar. 2026)


MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
65 GF Score
Price MXN1,150.00
GF Value MXN782.91
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Shares Outstanding (EOP)?

Ionis Pharmaceuticals MEX:IONS 65 Shares Outstanding (EOP) is 166 Mil as of Mar. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 65/100 and a GF Value™ of MXN782.91. The stock has 8 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Ionis Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 166 Mil.

Ionis Pharmaceuticals's quarterly shares outstanding increased from Dec. 2025 (163 Mil) to Mar. 2026 (166 Mil). It means Ionis Pharmaceuticals issued new shares from Dec. 2025 to Mar. 2026 .

Ionis Pharmaceuticals's annual shares outstanding increased from Dec. 2024 (158 Mil) to Dec. 2025 (163 Mil). It means Ionis Pharmaceuticals issued new shares from Dec. 2024 to Dec. 2025 .


Ionis Pharmaceuticals  (MEX:IONS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Ionis Pharmaceuticals Shares Outstanding (EOP) Related Terms


Ionis Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Shares Outstanding (EOP) Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 141.21 142.06 144.34 157.91 163.31

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 159.04 159.20 161.14 163.31 165.90

MEX:IONS vs EXEL, BBIO, AXSM: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Shares Outstanding (EOP) falls into.


MEX:IONS
65GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 166 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Shares Outstanding (EOP) of 166 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Shares Outstanding (EOP) too high?
Ionis Pharmaceuticals' current Shares Outstanding (EOP) is 166 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Shares Outstanding (EOP) compare to EXEL and BBIO?
Ionis Pharmaceuticals' Shares Outstanding (EOP) of 166 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Shares Outstanding (EOP) is 166 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Shares Outstanding (EOP) of 166 Mil. The stock's GF Value™ is MXN782.91, compared to a current price of MXN1,150.00 — trading 46.9% above its estimated fair value. The current Shares Outstanding (EOP) is 166 Mil. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Shares Outstanding (EOP) is 166 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 46.9% above its estimated GF Value™ of MXN782.91.

Key valuation signals for MEX:IONS:

  • Shares Outstanding (EOP): 166 Mil
  • GF Value™: MXN782.91 vs. price of MXN1,150.00 (46.9% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score

Get the complete analysis for MEX:IONS

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN782.91
GF Value